Autolus Therapeutics (AUTL)
Autolus Therapeutics Statistics
Share Statistics
Autolus Therapeutics has 266.13M shares outstanding. The number of shares has increased by 0.03% in one year.
| Shares Outstanding | 266.13M |
| Shares Change (YoY) | 0.03% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 63.25% |
| Shares Floating | 240.32M |
| Failed to Deliver (FTD) Shares | 98.78K |
| FTD / Avg. Volume | 6.09% |
Short Selling Information
The latest short interest is 11.45M, so 4.3% of the outstanding shares have been sold short.
| Short Interest | 11.45M |
| Short % of Shares Out | 4.3% |
| Short % of Float | 5.67% |
| Short Ratio (days to cover) | 4.97 |
Valuation Ratios
The PE ratio is -2.72 and the forward PE ratio is -1.94. Autolus Therapeutics's PEG ratio is 0.1.
| PE Ratio | -2.72 |
| Forward PE | -1.94 |
| PS Ratio | 59.25 |
| Forward PS | 0.5 |
| PB Ratio | 1.4 |
| P/FCF Ratio | -2.49 |
| PEG Ratio | 0.1 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Autolus Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.88, with a Debt / Equity ratio of 0.12.
| Current Ratio | 10.88 |
| Quick Ratio | 10.81 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | -0.26 |
| Debt / FCF | -0.22 |
| Interest Coverage | -25.98 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $15.64K |
| Profits Per Employee | $-341.05K |
| Employee Count | 647 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 2.75 |
Taxes
| Income Tax | 1.53M |
| Effective Tax Rate | -0.7% |
Stock Price Statistics
The stock price has increased by -65% in the last 52 weeks. The beta is 2.06, so Autolus Therapeutics's price volatility has been higher than the market average.
| Beta | 2.06 |
| 52-Week Price Change | -65% |
| 50-Day Moving Average | 1.64 |
| 200-Day Moving Average | 2.94 |
| Relative Strength Index (RSI) | 46.93 |
| Average Volume (20 Days) | 1.62M |
Income Statement
In the last 12 months, Autolus Therapeutics had revenue of 10.12M and earned -220.66M in profits. Earnings per share was -0.86.
| Revenue | 10.12M |
| Gross Profit | -1.27M |
| Operating Income | -241.43M |
| Net Income | -220.66M |
| EBITDA | -202.12M |
| EBIT | -209.84M |
| Earnings Per Share (EPS) | -0.86 |
Balance Sheet
The company has 227.38M in cash and 52.63M in debt, giving a net cash position of 174.75M.
| Cash & Cash Equivalents | 227.38M |
| Total Debt | 52.63M |
| Net Cash | 174.75M |
| Retained Earnings | -1.1B |
| Total Assets | 782.73M |
| Working Capital | 600.19M |
Cash Flow
In the last 12 months, operating cash flow was -206.27M and capital expenditures 0, giving a free cash flow of -241.09M.
| Operating Cash Flow | -206.27M |
| Capital Expenditures | 0 |
| Free Cash Flow | -241.09M |
| FCF Per Share | -0.94 |
Margins
Gross margin is -12.52%, with operating and profit margins of -2385.63% and -2180.45%.
| Gross Margin | -12.52% |
| Operating Margin | -2385.63% |
| Pretax Margin | -2165.36% |
| Profit Margin | -2180.45% |
| EBITDA Margin | -1997.27% |
| EBIT Margin | -2385.63% |
| FCF Margin | -2382.31% |
Dividends & Yields
AUTL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for AUTL is $10, which is 614.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 614.3% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -1.32 |
| Piotroski F-Score | 4 |